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Muscle lipogenesis balances insulin 
sensitivity and strength through  
calcium signaling
Katsuhiko Funai,1 Haowei Song,1 Li Yin,1 Irfan J. Lodhi,1 Xiaochao Wei,1 Jun Yoshino,2  
Trey Coleman,1 and Clay F. Semenkovich1,3
1Division of Endocrinology, Metabolism and Lipid Research, 2Division of Geriatrics and Nutritional Science, Department of Medicine, and  
3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Exogenous dietary fat can induce obesity and promote diabetes, but endogenous fat production is not thought 
to affect skeletal muscle insulin resistance, an antecedent of metabolic disease. Unexpectedly, the lipogenic 
enzyme fatty acid synthase (FAS) was increased in the skeletal muscle of mice with diet-induced obesity and 
insulin resistance. Skeletal muscle–specific inactivation of FAS protected mice from insulin resistance without 
altering adiposity, specific inflammatory mediators of insulin signaling, or skeletal muscle levels of diacylglyc-
erol or ceramide. Increased insulin sensitivity despite high-fat feeding was driven by activation of AMPK with-
out affecting AMP content or the AMP/ATP ratio in resting skeletal muscle. AMPK was induced by elevated 
cytosolic calcium caused by impaired sarco/endoplasmic reticulum calcium ATPase (SERCA) activity due to 
altered phospholipid composition of the sarcoplasmic reticulum (SR), but came at the expense of decreased 
muscle strength. Thus, inhibition of skeletal muscle FAS prevents obesity-associated diabetes in mice, but also 
causes muscle weakness, which suggests that mammals have retained the capacity for lipogenesis in muscle to 
preserve physical performance in the setting of disrupted metabolic homeostasis.
Introduction
By 2050, 1 in 3 Americans may have obesity-related type 2 diabetes, 
an often lethal condition (1) characterized by insulin resistance (2, 3). 
Skeletal muscle insulin resistance accounts for approximately 90% 
of impaired glucose disposal in human type 2 diabetes (4), and 
abnormal lipid metabolism is implicated in this process (5). Manip-
ulating genes affecting different steps in lipid handling produces 
varying effects on glucose metabolism that have been interpreted 
to reflect increased insulin sensitivity with decreased intracellular 
fatty acid content (6–11). Despite this apparently inverse relation-
ship between lipid content and insulin sensitivity, there is no con-
sensus regarding how fatty acid flux in muscle affects insulin sen-
sitivity (12, 13). Unexplored is the possibility that endogenous lipid 
synthesis in skeletal muscle affects diabetes risk.
Fatty acid synthase (FAS) (14) uses products of the citric acid 
cycle to synthesize the saturated fatty acid palmitate, contributing 
to de novo lipogenesis. Skeletal muscle de novo lipogenesis is not 
thought to be a major contributor to total muscle fatty acid flux 
(15). However, several lines of evidence suggest that de novo lipo-
genesis may serve a signaling function independent of providing 
lipid storage (16). As one example, FAS generates an endogenous 
ligand for the nuclear receptor PPARα in liver (17). PPARα is also 
found in muscle, where its overexpression has been implicated in 
the pathogenesis of insulin resistance (18). These observations raise 
the possibility that fatty acid flux generated by skeletal muscle FAS 
could promote insulin resistance through activation of PPARα.
To test the hypothesis that FAS affects skeletal muscle insulin 
sensitivity, we selectively inactivated FAS in this tissue. Our find-
ings suggest that mice deficient in de novo lipogenesis were pro-
tected from skeletal muscle insulin resistance induced by high-fat 
diet (HFD) feeding. However, this protection did not appear to 
be mediated by PPARα. Instead, FAS deficiency in muscle altered 
the phospholipid composition and transport functions of the sar-
coplasmic reticulum (SR; a relative of the endoplasmic reticulum 
adapted to sequester calcium), leading to elevated cytosolic cal-
cium concentrations. Elevated intracellular calcium increased glu-
cose transport through AMPK, but this metabolic benefit came at 
the cost of decreasing physical performance. Improved insulin sen-
sitivity appeared to be physiologically connected to muscle fatigue 
through increased cytosolic calcium, which activated AMPK but 
likely prevents appropriate relaxation of muscle fibers, thus limit-
ing optimal subsequent contraction.
Results
Skeletal muscle FAS is associated with insulin resistance. 4 weeks of feed-
ing HFD to control mice predictably increased levels of glucose, 
insulin, and other metabolites affected by insulin resistance (see 
below). This intervention is known to decrease FAS expression 
at major sites of lipogenesis, such as liver and white adipose tis-
sue (19, 20). Surprisingly, HFD feeding did not suppress FAS in 
muscle: mRNA, protein, and enzyme activity of FAS were increased 
in skeletal muscle after 4 weeks of HFD feeding (Figure 1A and 
Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI65726DS1). FAS protein abun-
dance was greater in slow-twitch muscles that are susceptible to 
diet-induced insulin resistance (21), such as soleus (Figure 1B), 
which suggests that muscle FAS may promote insulin resistance. 
To address this possibility, we crossed mice bearing loxP sites in 
Fasn (22) with transgenic mice expressing Cre recombinase driven 
by the human α–skeletal actin promoter (23). This strategy yielded 
FAS knockout in skeletal muscle (FASKOS) mice.
FASKOS mice are protected from diet-induced skeletal muscle insulin 
resistance. FASKOS mice had deficient FAS expression in skeletal 
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muscle, but not in liver, heart, or pancreas (Figure 1, C and D, and 
Supplemental Figure 1B). There was no genotype-specific effect on 
body weight or composition, as determined by MRI, with chow or 
HFD feeding (Figure 2A). Tissue weights of skeletal muscles, liver, 
and adipose depots were unaffected in FASKOS mice (Figure 2, B 
and C). Serum levels of glucose, free fatty acids, triglycerides, and 
cholesterol as well as of insulin and leptin were higher in HFD- 
versus chow-fed animals, but these effects were the same in control 
and FASKOS mice (Figure 2, D and E). The total skeletal muscle 
content of triglycerides, free fatty acids, malonyl-CoA, diacylglyc-
erol (DAG), ceramide, and other sphingolipid species did not dif-
fer between HFD-fed control and FASKOS mice (Figure 3, A–E, 
and data not shown). These negative results are consistent with 
previous reports of low levels of lipogenic genes, including FAS, in 
skeletal muscle compared with expression of malonyl-CoA decar-
boxylase (15), which suggests that FAS does not have major effects 
on the total mass of lipids and lipid precursors in muscle.
Muscle FAS deletion did not alter metabolic rate, as measured by 
indirect calorimetry (Figure 4A). Respiratory quotient (RQ; reflect-
ing choice of carbohydrate or lipid for energy production, with a 
lower value indicating more lipid use) was decreased in HFD-fed 
control mice that were awake and eating (during the dark phase of 
a daily cycle; Figure 4B), suggestive of less postprandial carbohy-
drate metabolism consistent with HFD-induced insulin resistance. 
However, FASKOS mice were partially protected from this HFD-
induced attenuation of RQ in the dark phase (Figure 4B), indica-
tive of increased use of carbohydrates as fuel. To determine wheth-
er this preference for carbohydrate was due to increased insulin 
sensitivity, FASKOS mice were further metabolically phenotyped.
Glucose and insulin tolerance tests showed that with chow feed-
ing, FASKOS mice were indistinguishable from control mice (Fig-
ure 4, C and D). However, FASKOS mice were partially protected 
from HFD-induced glucose intolerance and insulin resistance 
(Figure 4, E and F). In hyperinsulinemic euglycemic clamp studies, 
the insulin-stimulated glucose disposal rate was 4-fold greater in 
FASKOS than in control mice, whereas there was no difference in 
the ability of insulin to suppress endogenous glucose production 
(mostly reflecting hepatic effects) or release of fatty acids from 
fat (Figure 5, A–E). The findings that increased glucose disposal 
occurred in the absence of differences in adiposity, potential circu-
lating contributors to insulin resistance, or metabolic rate (Figures 
2 and 4) suggest that muscle FAS deficiency increased insulin sen-
sitivity through effects intrinsic to muscle.
Muscle FAS deletion results in intrinsic AMPK activation. Insulin-stim-
ulated glucose uptake in skeletal muscle is mediated by transloca-
tion of GLUT4 to the cell surface (24). In muscles isolated after the 
clamp, GLUT4 abundance was not different between control and 
FASKOS mice (Figure 5F). There was also no effect of FAS deletion 
on phosphorylation of Akt (pAktThr308 and pAktSer473) or of its sub-
strate, glycogen synthase kinase–3 (GSK3), in insulin-stimulated 
muscles, which suggests that these mediators of insulin receptor 
signaling are not involved in the FASKOS phenotype. However, 
phosphorylation of Akt substrate of 160 kDa (AS160), an Akt sub-
strate Rab GTPase activating protein known to regulate GLUT4 
Figure 1
Induction of skeletal muscle FAS by HFD feeding and FASKOS mouse generation. (A) FAS mRNA, protein, and enzyme activity in soleus muscles 
from mice fed chow or HFD (n = 7 per group). (B) Western blot analyses of FAS protein expression in various muscles (top) and tissues (bottom). 
GW, gastrocnemius (white); GR, gastrocnemius (red); TA, tibialis anterior; Epi, epitrochlearis; Vast, vastus lateralis; Diaph, diaphragm; COXIV, 
mitochondrial cytochrome c oxidase subunit IV. (C) FAS Western blots from muscles (top) and other tissues (bottom) in control and FASKOS 
mice. (D) FAS mRNA (n = 6 per genotype), protein (n = 7 per genotype), and enzyme activity (n = 10 per genotype) in control and FASKOS mice. 
Data are mean ± SEM.
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translocation (25, 26), was increased in the muscles from FASKOS 
compared with control mice (Figure 5F). AS160 phosphorylation 
is permissive for glucose transport. In addition to Akt, AMPK can 
phosphorylate AS160 (27, 28). Phosphorylation of AMPK and its 
substrate, acetyl-CoA carboxylase (ACC), were found to be elevated 
in FASKOS versus control mice (Figure 5F). Because AMPK 
enhances muscle insulin sensitivity, these results suggest that the 
insulin sensitivity phenotype in HFD FASKOS mice may be due to 
muscle-intrinsic AMPK activation.
Soleus muscles were isolated from control and FASKOS mice fed 
chow or HFD, then incubated with 2-deoxyglucose. As with intact 
animals, there was no effect of FAS inactivation 
in the chow condition, but soleus and extensor 
digitorum longus (EDL) muscles isolated from 
FASKOS mice were partially protected from the 
HFD-induced reduction of insulin-stimulated 
glucose uptake (Figure 6A and Supplemental 
Figure 2). Western blotting of these isolated 
muscles confirmed the findings of others that 
HFD decreased AMPK activation in control 
muscles (29, 30) and showed that FASKOS 
muscles were protected from this suppression 
of AMPK activation (reflected as phosphoryla-
tion of AMPK itself as well as of ACC; Figure 6, 
B and C). Mirroring the findings in intact mice, 
Akt activation was unaffected, whereas AS160 
phosphorylation was increased, in muscle of HFD-fed FASKOS 
mice (Figure 6, D and E). These observations suggest that FASKOS 
muscle is protected from HFD-induced suppression of AMPK 
activity and, since HFD feeding increased muscle FAS activity (Fig-
ure 1A), that skeletal muscle FAS inhibits AMPK activation.
Muscle-intrinsic AMPK activation is mediated by increased cytosolic cal-
cium. To determine whether regulation of AMPK by FAS can be 
modeled in a cell line, C2C12 myocytes were treated with a lentivi-
rus expressing an FAS shRNA. C2C12 cells are a transformed cell 
line with metabolic needs differing from those of intact muscle, 
but there is precedent for the use of these cells to gain insight into 
Figure 2
Phenotyping of FASKOS mice. (A) Body weight and composition of control and FASKOS mice (n = 8 per genotype). (B and C) Soleus and EDL 
weights (B) and liver and adipose tissue weights (C) in HFD-fed control and FASKOS mice (n = 7 per genotype). (D) Serum chemistries. (E) 
Serum hormones. Data are mean ± SEM.
Figure 3
Skeletal muscle metabolites in HFD-fed control and 
FASKOS mice. (A) Triglycerides, (B) free fatty acids, 
(C) malonyl-CoA, (D) DAG species, and (E) ceramide 
species (n = 4 per group). Data are mean ± SEM.
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processes relevant to the role of muscle in physiology (31). FAS 
knockdown (FASKD) had no effect on activation of Akt or GSK3 
compared with control cells treated with a scrambled virus, but 
increased phosphorylation of AMPK as well as of its targets, ACC 
and AS160 (Figure 7A), replicating the effects in FASKOS skeletal 
muscle. FAS generates an endogenous ligand for the nuclear recep-
tor PPARα in liver (17), and PPARα deletion activates AMPK in 
skeletal muscle (18), which raises the possibility that FAS deletion 
affects AMPK through PPARα. However, FAS deletion did not 
affect PPARα luciferase activity, and treatment with the PPARα 
agonist WY14643 did not reverse FASKD-induced AMPK activa-
tion (Figure 7, B and C). AMPK can be allosterically activated by 
AMP, but AMP content and the AMP/ATP ratio were unaffected 
by FAS deletion (Supplemental Figure 3, A and B). Total skeletal 
muscle malonyl-CoA levels were not different between control 
and FASKOS mice (Figure 3C). It is conceivable that changes in 
malonyl-CoA limited to discrete subcellular compartments might 
activate AMPK by inhibiting carnitine palmitoyl transferase–1 and 
fatty acid oxidation. However, incubation of C2C12 myocytes with 
the fatty acid oxidation inhibitor etomoxir did not alter AMPK 
signaling (data not shown), and fatty acid oxi-
dation rates were not different from controls in 
muscles or C2C12 cells with FAS deletion (Sup-
plemental Figure 3, C and D). Inflammation can 
play a role in insulin sensitivity, but there was no 
effect of FAS deletion on JNK or IκBα activity in 
skeletal muscle (Supplemental Figure 4). There 
was also no detectable interaction between 
FAS and AMPK in co-IP experiments (data not 
shown). Therefore, the effect of muscle FAS 
deletion on AMPK activation does not appear 
to be mediated by PPARα, AMP levels, altered 
fatty acid oxidation, inflammation, or a direct 
effect of FAS on AMPK.
AMPK can be phosphorylated by liver kinase 
B1 (LKB1) or Ca2+/calmodulin-dependent 
kinase kinase–β (CaMKKβ). FASKD did not 
affect mRNA levels or protein abundance of 
LKB1, CaMKKα, or CaMKKβ (Supplemental 
Figure 5). LKB1 appears to be constitutively 
active, but CaMKKβ is activated by increased 
cytosolic calcium (32). Since FAS inactivation in 
cardiac muscle increases calcium signaling (33), 
and calcium (34), calmodulin (35), and CaMKII 
(36) have been implicated in glucose uptake, we 
addressed a potential role for calcium. In C2C12 
myocytes, cytosolic calcium content increased 
in response to FASKD (Figure 7, D and E). 
The increase in cytosolic calcium triggered the 
Ca2+/calmodulin signaling cascade in C2C12 
myocytes (Figure 8, A and B). Activation of CaMKKβ (detected 
as CaMKI phosphorylation) was also found in clamped as well 
as isolated FASKOS muscles (Figure 8, C and D). To determine 
whether CaMKKβ was required for the effect of FAS deletion on 
AMPK activation, we inhibited CaMKKβ in the setting of FASKD 
in C2C12 myocytes. FASKD-induced AMPK activation was abro-
gated by CaMKKβ knockdown, which was confirmed by treatment 
with a chemical inhibitor of CaMKK, STO-609 (Figure 8, E and 
F). These data suggest that induction of AMPK activity with FAS 
deletion is related to increased calcium signaling.
Muscle FAS affects SERCA by altering SR phospholipid composi-
tion. Control of cytosolic calcium in skeletal muscle is mediated 
by transporters found at the plasma membrane and at the SR. 
Dogma holds that FAS is exclusively cytoplasmic, but subcellu-
lar fractionation studies of skeletal muscle unexpectedly showed 
that, in addition to the cytoplasm, SR was also highly enriched 
in FAS (Figure 9A). To address the possibility that FAS physically 
interacts with SR proteins to regulate calcium flux, the SR frac-
tion from mouse hindlimb muscles was treated with an FAS anti-
body, and the immunoprecipitated proteins were identified by 
Figure 4
FASKOS mice are protected from diet-induced 
whole-body glucose intolerance and insulin resis-
tance. (A) VO2 in control and FASKOS mice. (B) 
RQ. (C–F) Glucose tolerance tests (GTT; C and E) 
and insulin tolerance tests (ITT; D and F) in mice 
fed chow (C and D) or HFD (E and F). n = 5 (A and 
B), 10 (C, D, and F), or 12 (E) per genotype. Data 
are mean ± SEM.
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mass spectrometry (Supplemental Table 1). It is likely that several 
of these proteins do not reside in the SR, given the sensitivity of 
mass spectrometry and possible contamination of the SR fraction 
with proteins from other compartments. However, 3 isoforms 
of sarco/endoplasmic reticulum calcium ATPase (SERCA), 
the ATPase that transports cytosolic calcium to the SR lumen, 
were detected. Results of co-IP experiments using SERCA1 and 
SERCA2 antibodies were consistent with an association between 
these 2 proteins and FAS (Figure 9B). ACC did not appear to 
interact with the SERCAs (Figure 9B). Immunofluorescence colo-
calization studies in C2C12 cells also suggested an interaction 
between FAS and SERCA1 (Figure 9C). FAS also colocalized with 
the endoplasmic reticulum/SR marker calnexin, but not with the 
Golgi marker GM130 (Figure 9C). FASKD in C2C12 myocytes 
decreased SERCA enzyme activity without affecting SERCA1 pro-
tein abundance (Figure 9D). Transfecting C2C12 myocytes with 
a vector expressing myc-tagged SERCA1 restored SERCA enzyme 
activity (Figure 9D). Expressing myc-tagged SERCA1 also elimi-
nated the FASKD-induced increase in AMPK phosphorylation 
(Figure 9E), consistent with the concept that FAS inactivation 
impairs SERCA activity to activate AMPK. FASKD did not affect 
myc-tagged SERCA1 expression (Figure 9E). In addition, SERCA 
enzyme activity was decreased in soleus and EDL muscle of HFD-
fed, but not chow-fed, FASKOS mice without affecting SERCA1 
protein abundance (Figure 9F and Supplemental Figure 6). These 
data suggest that FAS promotes SERCA activity in muscle and 
that a reduction in SERCA activity may mediate AMPK activation 
and increased insulin sensitivity in FAS-deficient muscles.
FAS is involved in palmitoylation of certain proteins to promote 
their membrane association (37, 38). However, neither SERCA1 nor 
SERCA2 was palmitoylated in sensitive assays involving replace-
ment of biotin for palmitate at cysteine residues (data not shown).
To determine whether the lipid environment of the SR is altered 
by FAS deficiency, the SR fraction of hindlimb muscle was isolated 
and analyzed by mass spectrometry. The ratio of phosphatidyl-
choline (PC) to phosphatidylethanolamine (PE) was not affected 
by FAS deficiency in the SR with chow feeding, but increased in 
the SR of HFD-fed FASKOS muscle (Figure 10A). This change 
reflected the relative lack of a HFD-induced increase in PE con-
tent and a more robust HFD-induced increase in PC content in 
FASKOS mice (Figure 10, B and C). For PE, the SR changes were 
particularly pronounced for a specific species, 16:0/22:6 PE (Fig-
ure 10D). For PC, several species were affected, most prominently 
16:1/18:1 PC (Figure 10E). Under chow- and HFD-fed conditions, 
skeletal muscle FAS deletion did not affect PC or PE content in the 
nucleus or mitochondria (Supplemental Figures 7 and 8). How-
ever, FASKD in C2C12 cells was associated with an increased PC/
PE ratio and decreased PE content in the SR (Supplemental Fig-
ure 9). PE is known to increase the affinity of calcium for SERCA 
(39), and an increased PC/PE ratio is associated with decreased 
SERCA activity in mouse liver (40), which suggests that altered 
lipid composition of the SR mediates decreased SERCA activity in 
FASKOS muscle. Note that the SERCA activity pattern for control 
and FASKD C2C12 cells was inversely related to the PC/PE ratio 
in SR of C2C12 cells (Figure 9D and Supplemental Figure 9); the 
SERCA activity pattern for muscle of HFD-fed control and FAS-
KOS mice was also inversely related to the SR PC/PE ratio for this 
muscle (Figure 9F and Figure 10A).
FASKOS mice are prone to diet-induced muscle weakness. SERCA is 
critical for muscle contraction, allowing fiber relaxation through 
the efficient uptake of cytosolic calcium. Force production is 
profoundly decreased in SERCA1-null mice (41). Conversely, 
SERCA1 overexpression improves muscle capacity in muscular 
dystrophy (42). As shown in Figure 11A, forelimb strength paral-
leled SERCA activity (Figure 9F) in FASKOS mice: strength was 
unaffected on a chow diet but decreased with HFD feeding. This 
muscle contractile abnormality was also demonstrated when 
HFD-fed FASKOS mice were subjected to high-intensity tread-
mill running. FASKOS mice performed less well than control 
mice in terms of both running time and distance (Figure 11, B 
and C, and Supplemental Video 1). These observations suggest 
that while FAS deletion in skeletal muscle triggers calcium sig-
naling benefiting glucose homeostasis, this effect compromises 
skeletal muscle contractile function.
Figure 5
Hyperinsulinemic euglycemic clamp stud-
ies in HFD-fed control and FASKOS mice. 
(A) Glucose infusion rate (GIR), (B) glu-
cose disposal rate (GDR; during clamp 
phase), (C) insulin-stimulated glucose dis-
posal rate (IS-GDR; calculated difference 
between clamp and basal phases), and 
(D) suppression of hepatic glucose produc-
tion (HGP) (n = 10 [control]; 8 [FASKOS]). 
(E) Circulating free fatty acids during basal 
and clamp phase (n = 7 per genotype). (F) 
Western blot analyses of soleus from clamp 
studies. Data are mean ± SEM.
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Discussion
Synthesizing fatty acids in skeletal muscle would not be predicted 
to be relevant to HFD-induced insulin resistance. Since FAS is 
decreased by exogenous fat in lipogenic tissues (19, 20), one might 
also anticipate that excess dietary fat would decrease FAS in muscle. 
Unexpectedly, we found that HFD feeding increased FAS activity 
in skeletal muscle of control mice in concert with the induction 
of insulin resistance. FASKOS mice, with skeletal muscle–specific 
inactivation of FAS, were partially protected from diet-induced 
insulin resistance, but also prone to diet-induced muscle weakness.
The underlying mechanism involves an effect of FAS on the 
modulation of cytosolic calcium. We found that FAS, thought to 
be exclusively cytosolic, was also present in the SR fraction of skel-
etal muscle, where it is physically associated with SERCA proteins. 
FAS deficiency decreased SERCA activity by altering the phospho-
lipid composition of the SR, which resulted in increased cytosolic 
calcium. Decreased uptake of cytosolic calcium led to CaMKKβ-
dependent activation of AMPK to improve 
glucose metabolism. However, altered calcium 
handling prevented normal muscle relaxation, 
leading to disruption of subsequent contraction 
manifested as decreased overall muscle perfor-
mance. At the sarcomere, cytosolic calcium binds 
troponin to release tropomyosin from actin, thus 
permitting myosin-induced ATP-dependent 
muscle contraction. During normal relaxation, 
cytosolic calcium is taken up by the SR, leading 
to actin-myosin dissociation. Calcium cycling 
between SR and the cytosol is strictly regulated 
in striated muscles, and its disruption causes 
muscle dysfunction (43). Figure 12 depicts the 
potential relationship among FAS, insulin sensi-
tivity, and weakness in skeletal muscle.
FAS is linked to the generation of phospholip-
id species that activate nuclear receptors (17, 44), 
consistent with the possibility that FAS is part of 
a synthetic pathway leading to the production 
of phospholipids, such as certain PE species, at 
the SR. However, our data did not establish that 
FAS enzyme activity is required for effects on SR 
composition. It is possible that FAS interacts 
with the SR or SERCA to alter the PC/PE ratio 
independent of its capacity to convert malonyl-
CoA into palmitate.
Lipids are implicated in the pathogenesis of 
diet-induced skeletal muscle insulin resistance. 
This phenomenon is incompletely understood, 
but a popular explanation is the accumulation 
of lipid species such as DAG and ceramide that 
may induce stress kinases, leading to decreased 
insulin-stimulated Akt phosphorylation (24, 
45). Perhaps underappreciated is reduced muscle 
AMPK activity in insulin resistance (29, 30). Skeletal muscles from 
FASKOS mice were not protected from HFD-induced suppres-
sion of insulin-stimulated Akt phosphorylation, but they were 
protected from a HFD-induced reduction in AMPK activity. DAG, 
ceramide, and the activities of certain stress kinases were not dif-
ferent in muscles from HFD-fed control and FASKOS mice, which 
suggests that these mediators are not likely contributors to the 
insulin sensitivity of FASKOS muscle. Our observations indicate 
that the insulin-sensitizing phenotype with FAS deficiency is 
mediated by AMPK, not Akt, and suggest that multiple pathways 
may be involved in muscle insulin resistance.
FAS affects activity of the nuclear receptor PPARα in liver (17, 
22), brain (46), and macrophages (47), and overexpression of 
PPARα in skeletal muscle causes insulin resistance and inacti-
vates AMPK (18), which led us to consider PPARα as a mediator 
of the FASKOS phenotype. However, FAS inactivation in muscle 
did not affect activity of a PPARα reporter gene, and treatment 
Figure 6
Isolated soleus muscle studies. (A) 2-deoxyglucose 
(2DG) uptake, (B) pAMPKThr172, (C) pACCSer79, (D) 
pAktThr308, and (E) pAS160Thr642 (n = 6 per group). 
Data are mean ± SEM. Representative blots from 
muscles are also shown.
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with a potent PPARα agonist did not rescue the effect of FAS 
deletion on AMPK signaling. Similarly, inactivation of FAS in 
cardiac muscle did not affect PPARα target genes, but instead 
activated calcium signaling pathways (33) through incompletely 
defined mechanisms. The calcium-regulatory mechanism shown 
here in skeletal muscle may also be involved in the phenotype of 
mice with FAS knockout in heart (33), another tissue adapted 
for contractile function, but its relevance to other tissue-specific 
FAS knockouts is uncertain. Inactivation of pancreatic β cell FAS 
has no effect on insulin secretion, a process requiring dynamic 
Figure 7
Muscle FAS deletion does not affect PPARα activity, but increases cytosolic calcium. (A) Western blot analyses of scrambled (SC) or FASKD 
C2C12 myocytes. (B) PPARα luciferase activity in scrambled or FASKD C2C12 myocytes with or without the PPARα agonist WY14643 (n = 8 
replicate measurements per bar). (C) Western blot analyses of scrambled or FASKD C2C12 myocytes with or without WY14643. (D) Cytosolic 
calcium in scrambled and FASKD C2C12 myocytes measured using fluo-8 AM. Original magnification, ×100. (E) Quantified fluo-8 AM fluores-
cence in scrambled and FASKD C2C12 myocytes (n = 12 culture wells per condition; horizontal lines denote means). Data are mean ± SEM.
Figure 8
Muscle FAS deletion induces calcium signaling and activates AMPK through CaMKKβ. (A) Calcium signaling cascade affected by muscle FAS 
deletion. PLB, phospholamban. (B–D) Western blot analyses for calcium signaling proteins (n = 6 per group). Data are mean ± SEM. Representative 
blots are also shown. (B) C2C12 myocytes. Phospholamban is phosphorylated by CaMKII on Thr17 and by PKA on Ser16. (C) Muscle from clamp 
studies of HFD-fed animals. (D) Isolated soleus muscle. (E) Western blot analyses of C2C12 myocytes after FASKD and CaMKKβ knockdown. (F) 
Incubation of C2C12 myocytes with the CaMKK inhibitor STO-609 (10 μg/ml for 6 hours) eliminated FASKD-induced activation of AMPK signaling. 
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Figure 9
Muscle FAS deletion decreases SERCA activity. (A) Differential centrifugation of mouse hindlimb muscles. PM, plasma membrane; GM130, 
130-kDa cis-Golgi matrix protein. (B) Soleus co-IP experiments. FAS, but not ACC, coimmunoprecipitated with SERCA1 or SERCA2 antibody; 
SERCA1 and SERCA2 coimmunoprecipitated with FAS antibody, but not with ACC antibody. (C) Confocal images of C2C12 cells. Original mag-
nification, ×630. Boxed regions are shown enlarged (×4-fold) at far right. (D) Rescue of the FASKD-induced reduction in SERCA enzyme activity 
by expression of myc-SERCA1 (n = 8 replicates per condition). Moreover, SR SERCA abundance with vector treatment was not altered by FASKD 
(bottom). (E) Expression of myc-SERCA1 reversed FASKD-induced increase in pAMPK. (F) SERCA activity in soleus from chow- or HFD-fed 
control and FASKOS mice (n = 6 per group). SR SERCA abundance is also shown. Data are mean ± SEM.
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prompted the selection of animals with the capacity to increase 
FAS activity in muscle and maintain SERCA activity in order to 
escape other predators attracted by the same high-fat prey. It has 
been suggested that insulin resistance is a normal physiological 
response that limits obesity through mobilization of substrates 
(51). Our results suggest that, in addition to defending against 
obesity, insulin resistance maintains muscle strength in the set-
ting of nutrient excess. A HFD-induced increase in skeletal muscle 
FAS would preserve SERCA activity and normalize force-generat-
ing capacity, perhaps selected by evolutionary pressures. It would 
also increase insulin resistance, probably unrelated to evolution-
ary pressures since the complications of insulin resistance become 
manifest well after the next generation is spawned.
Diabetes may have complex effects on skeletal muscle calcium 
metabolism, since SERCA is decreased in the diabetic soleus 
muscle (52) and insulin receptor substrate proteins interact with 
SERCA (53). FAS inhibitors may be useful for treating type 2 dia-
betes (54). Our findings suggest that these agents might lower 
blood sugar at the expense of muscle function, identifying a possi-
ble side effect of a new class of medication, but also representing a 
potentially reasonable exchange for modern humans who need to 
escape the consequences of abnormal glucose metabolism instead 
of another mammal looking for a meal.
Methods
Further details are provided in Supplemental Methods.
Animals. Mice with a floxed Fasn locus (Fasnfl/fl) were crossed with trans-
genic mice expressing Cre recombinase under the control of the human 
α–skeletal actin (HSA) promoter to obtain FASKOS mice in the C57BL/6J 
regulation of intracellular calcium (46), which suggests that in 
this model, the loss of FAS does not have a major impact on the 
calcium flux required to release insulin-secretory granules. How-
ever, it is possible that the loss of FAS in other nonmuscle tissues 
alters calcium signaling.
Our data suggest that the induction of FAS by HFD feeding 
may contribute to skeletal muscle insulin resistance. Although 
not extensively studied in muscle, FAS regulation involves insulin 
signaling, the induction of the transcription factor SREBP1c (also 
known as SREBF1), and other factors (48). In humans, skeletal 
muscle expression of SREBP1c is highest in individuals that are 
most insulin resistant (49). This observation is consistent with our 
present findings in mice, supporting the plausibility of SREBP1c-
driven genes such as FAS being increased in muscle in the setting 
of diet-induced insulin resistance. HFD feeding has been reported 
to increase SERCA activity in soleus muscle under certain condi-
tions (50), also consistent with our observations linking HFD feed-
ing, FAS, and SERCA.
It is tempting to speculate that HFD-induced FAS expression 
in muscle represents a selective advantage for mammals. Skel-
etal muscle’s raison d’être is contraction, required for acquiring 
food, escaping predators, and finding a mate. A HFD-induced 
increase in muscle FAS may promote insulin resistance, but it may 
also optimize contractile function. When evolutionary pressures 
were substantial, mammalian meals were infrequent but high in 
fat, especially if they consisted of other mammals. Our ancestors 
probably fasted for prolonged periods while hunting, then feasted 
for prolonged periods on high-fat prey. Disruption of metabol-
ic homeostasis induced by HFD feeding after fasting may have 
Figure 10
Muscle FAS deletion alters SR phospholipid composition. Mass spectrometry quantification of (A) relative PE and PC abundance, (B and C) total 
PE and PC, and (D and E) PE and PC species in isolated SR from hindlimb muscles of chow- or HFD-fed control and FASKOS mice (n = 4–6). 
Data are mean ± SEM.
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cDNA insert (Open Biosystems) by PCR, using the following primers (under-
line denotes XhoI and XbaI sites): 5′-CTCGAGATGGAGGCCGCGCACTC-
CAAGTCC-3′ and 5′-TCTAGATTATCCCTCCAGATAGTTCCGAGC-3′. The 
amplified product was subcloned into the pRK5-myc plasmid at its XhoI 
(5′) and XbaI (3′) sites to yield an N-terminal myc-tagged construct (pRK5-
myc-mSERCA1). Transfection-ready pCMV6-XL4-SERCA2 plasmids were 
purchased from OriGene Technologies. All plasmids were sequenced to 
confirm their identity and orientation. Differentiated scrambled or FASKD 
C2C12 myocytes were transfected with pRK5-myc-mSERCA1 or pCMV6-
XL4-SERCA2 using Lipofectamine 2000 (Invitrogen).
IP. Homogenates were incubated with antibodies (anti-FAS [ab22759], 
anti-SERCA1 [ab2818], and anti-SERCA2 [ab3625]; Abcam) or normal 
rabbit serum on a rotator overnight at 4°C. Protein A agarose beads were 
added to the homogenate-antibody mixture for an additional 2 hours at 
4°C. Beads were washed 5 times with PBS, mixed with 2× Laemmli sample 
buffer, heated at 95°C for 5 minutes, and then subjected to SDS-PAGE for 
analysis by Western blotting or mass spectrometry.
SERCA activity assay. The calcium transport assay for measuring SERCA 
activity was adapted from a protocol described previously (58). SR fractions 
from C2C12 myocytes or skeletal muscles were isolated by differential cen-
trifugation. The assay mixture contained 100 mM KCl, 30 mM imidazole-
histidine (pH 6.8), 5 mM MgCl2, 5 mM ATP, 5 mM (COOK)2, 5 mM NaN3, 
1 μM Rethenium Red, and 50 μM CaCl2 (1 μCi/μmol [45Ca]CaCl2; Ameri-
can Radiolabeled Chemicals). The reaction was started by the addition of 
SR fractions containing 150 μg protein for 15 minutes in a 37°C water 
bath, stopped by the addition of 0.15 M KCl and 1 mM LaCl3, and filtered 
through a 0.2-μm HT Tuffryn membrane (Pall Corp.). SERCA-independent 
calcium transport was quantified in the presence of 10 μM thapsigargin.
background. Fasn and Cre genotyping was performed as described previ-
ously (22). Chow diet and HFD were Purina 4043 and Harlan Teklad TD 
88137, respectively. Male mice aged 8–12 weeks were used for all experi-
ments. Controls were either Fasnfl/fl mice without the Cre transgene or mice 
with the Cre transgene alone. The presence of Cre transgene alone did not 
affect glucose metabolism compared with Fasnfl/fl mice without the trans-
gene (data not shown).
Indirect calorimetry. Indirect calorimetry was performed as described 
previously (55). O2 consumption (VO2) and CO2 production were mea-
sured for 24 hours. Mean relative VO2 (expressed in ml/kg/min) and 
respiratory quotient (RQ; calculated as VCO2/VO2) were determined for 
dark and light periods.
AMP and ATP measurements. Frozen muscles were treated with perchlo-
ric acid and neutralized with K2CO3 on ice, and then levels were assayed 
by HPLC as described previously (56). AMP and ATP were quantified 
based on peak area compared with a standard curve and normalized to 
frozen tissue weight.
Fatty acid oxidation determinations. Muscles or cells were processed exactly 
as described previously (44) in an assay after the conversion of labeled pal-
mitate to labeled CO2 that is trapped in filter paper. Rates of fatty acid 
oxidation were calculated as nmol 14CO2 produced per hour, normalized 
to tissue weight or cellular protein.
Treadmill sprint interval exercise tests. Mouse treadmill exercise tests used a 
recently described protocol (57). Fed mice ran intervals of 1 minute each, 
with a 2-minute rest between each interval. Running started at a rate of 
10 m/min and increased by 5 m/min at each interval.
Ectopic expression of SERCA1 and SERCA2. The cDNA encoding the mouse 
enzyme SERCA1 was cloned from pCMV-SPORT6 with mouse SERCA1 
Figure 11
FASKOS mice are weak. (A) Forelimb strength in chow- 
or HFD-fed control and FASKOS mice (n = 7 per group). 
(B and C) Total running time and distance of HFD-fed mice 
with treadmill sprint interval exercise tests (n = 6 per group). 
Data are mean ± SEM.
Figure 12
FAS-driven modulation of SERCA activity and cytosolic calcium leads to 
increased insulin sensitivity and muscle weakness. Increased cytosolic 
calcium after FAS inactivation likely impairs relaxation of the actin-myo-
sin junction at the sarcomere, promoting muscle weakness. Calcium 
also likely activates a signaling cascade involving CaMKKβ, AMPK, and 
AS160 that enhances insulin-stimulated glucose uptake in muscle.
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analyses) or 2-way ANOVA with Student-Newman-Keuls post-hoc test (for 
2-by-2 comparisons). A P value less than 0.05 was considered significant.
Study approval. The Washington University Animal Studies Committee 
approved all protocols.
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FAS activity assay. FAS enzyme activity was determined using a modifica-
tion of a previously described assay (59). Freshly harvested muscles were 
weighed and homogenized in 0.1 M potassium phosphate buffer (pH 7.0) 
containing 8% sucrose, 1 mM EDTA (pH 8.0), and 20 mM 2-mercapto-
ethanol at 4°C. Homogenates were centrifuged at 3,000 g for 10 minutes 
at 4°C. 10 μl of the supernatant was added to 80 μl of assay buffer (0.14 M 
potassium phosphate buffer [pH 7.0], 1.4 mM EDTA [pH 8.0], 1.4 mM 
DTT, 0.24 mM NADPH, and 0.1 mM acetyl-CoA), and the rate of NADPH 
oxidation was monitored at 340 nm. The substrate-dependent rate was 
determined by subtracting the NADPH oxidation rate from the rate after 
adding 10 μl of 1 mM malonyl-CoA.
Measurement of malonyl-CoA content. Soleus muscles were harvested from 
mice after a 6-hour fast. Malonyl-CoA was determined in extracts homog-
enized in deionized water. CoA esters were separated using reverse-phase 
HPLC on a 5 μm Supelco C18 column with a Waters HPLC system, moni-
toring 254 nm as the maximal absorbance for CoA. Buffers, gradients, and 
flow rates were described previously (60).
Statistics. Values are expressed as mean ± SEM. Statistical comparisons 
were performed using an unpaired 2-tailed Student’s t test (for 2-group 
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